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Abstract
Objective
There is debate on how the methodological quality of clinical trials should be assessed. We
compared trials of physical therapy (PT) judged to be of adequate quality based on sum-
mary scores from the Physiotherapy Evidence Database (PEDro) scale with trials judged to
be of adequate quality by Cochrane Risk of Bias criteria.
Design
Meta-epidemiological study within Cochrane Database of Systematic Reviews.
Methods
Meta-analyses of PT trials were identified in the Cochrane Database of Systematic
Reviews. For each trial PeDro and Cochrane assessments were extracted from the PeDro
and Cochrane databases. Adequate quality was defined as adequate generation of random
sequence, concealment of allocation, and blinding of outcome assessors (Cochrane crite-
ria) or as trials with a PEDro summary score5 or6 points. We combined trials of ade-
quate quality using random-effects meta-analysis.
Results
Forty-one Cochrane reviews and 353 PT trials were included. All meta-analyses included
trials with PEDro scores5, 37 (90.2%) included trials with PEDro scores6 and only 22
(53.7%) meta-analyses included trials of adequate quality according to the Cochrane crite-
ria. Agreement between PeDro and Cochrane was poor for PeDro scores of5 points
(kappa = 0.12; 95% CI 0.07 to 0.16) and slight for6 points (kappa 0.24; 95% CI 0.16-
0.32). When combining effect sizes of trials deemed to be of adequate quality according to
PEDro or Cochrane criteria, we found that a substantial difference in the combined effect
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size (0.15) was evident in 9 (22%) out of the 41 meta-analyses for PEDro cutoff5 and 10
(24%) for cutoff6.
Conclusions
The PeDro and Cochrane approaches lead to different sets of trials of adequate quality, and
different combined treatment estimates from meta-analyses of these trials. A consistent
approach to assessing RoB in trials of physical therapy should be adopted.
Introduction
Randomized controlled trials (RCTs) are the design of choice when comparing two or more
healthcare interventions. Appropriately conducted RCTs minimize confounding and bias and
thus allow causal inferences regarding the effects of interventions. However, when not appro-
priately done, RCTs may yield biased estimates [1–6]. Thus, it is imperative to consider the risk
of bias (RoB) in RCTs when reviewing evidence for clinical decision making.
The importance of incorporating RoB assessments in evidence synthesis is widely recog-
nized. It is good practice to ascertain whether or not results differ between trials at greater or
lesser RoB. However, the approaches to perform such assessments have been inconsistent: a
wide variety of checklists and scales have been developed to evaluate RoB in RCTs [7–9]. The
use of different items varies between tools, some items are used without empirical evidence or
theoretical rationale, and different checklists and scales are used in different research areas,
suggesting lack of agreement regarding their relevance [7].
The use of summary scores from quality scales, where a study typically receives one point
for each item met by the study has been criticized on several grounds [10, 11]. The effects of
essential criteria, such as concealment of allocation, may be diluted or confounded by the sum-
mary quality score, if the latter includes items not related to RoB, or not important in a given
context. Indeed, items that are important in some situations may not be relevant in other situa-
tions, yet they receive the same weight in the quality scale [10, 11]. For example, blinding of
study participants is crucial for pain assessment or management, but irrelevant for all-cause
mortality [12]. Therefore, the Cochrane Bias Methods Group and Statistical Methods Group
recommend that summary scores obtained from quality scales should not be used [13]. Rather,
relevant biases should be assessed one by one, including the domains of selection bias, perfor-
mance bias, detection bias, attrition bias, reporting bias and other context-specific biases [14].
The debate on how best to assess the risk of bias of RCTs included in meta-analytic research
has resurfaced recently in the field of physical therapy, where the Physiotherapy Evidence
Database (PEDro) scale is widely used [12, 15]. Ten items (see S1 Table) contribute to a sum-
mary score, where a score of 5 or 6 typically defines adequate trial quality [12, 16–18]. Most
items relate to design biases but others concern trial reporting, for example whether or not con-
fidence intervals or other measures of variability were included in the article.
We performed a meta-epidemiological study of Cochrane systematic reviews and meta-
analyses in physical therapy. Our aim was to determine the agreement between the Cochrane
and the PeDro approaches to identifying physiotherapy trials of adequate quality and to exam-
ine whether or not the approach chosen (PEDro or Cochrane) may affect the conclusions of
meta-analyses in physical therapy.
Treatment Effects Differed between PeDro Score and Cochrane Approach
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Methods
Literature search and eligibility criteria
We searched the Cochrane Database of Systematic Reviews (CDSR) from Jan 1 2005 to May 25
2011 for meta-analyses of physical therapy interventions using the free-text words ‘physical
therapy’, ‘physiotherapy’, ‘rehabilitation’, ‘exercise’, ‘electrophysical agents’, ‘acupuncture’,
‘massage’, ‘transcutaneous electrical stimulation (TENS)’, ‘interferential current’, ‘ultrasound’,
‘stretching’, ‘chest therapy’, ‘pulmonary rehabilitation’, ‘manipulative therapy’, ‘mobilization’,
and related terms. For the detailed search strategy see S1 Appendix. Meta-analyses were eligible
if they included at least three RCTs of physical therapy interventions according to the World
Confederation for Physical Therapy (WCPT) [19] with a continuous outcome. If there were
several eligible outcomes, we chose the primary outcome as specified by the authors. If the pri-
mary outcome was not eligible or not specified, the outcome that contained the largest number
of trials was chosen.
PEDro Scores and Cochrane RoB assessment
When available, quality assessments of RCTs included in reviews were obtained from the
PEDro database [16] (see also http://www.pedro.org.au) or the Cochrane reviews. If a trial was
not included in the PEDro database or no Cochrane RoB assessment had been done, we per-
formed the assessments ourselves. Two reviewers (CH, DP, AC, JF, or HS) independently
assessed trials, with discrepancies resolved by discussion or consultation with S.A-O. We
trained assessors using 10 trials not included in the study, based on relevant guidelines [13, 14,
20]. As described in detail elsewhere, the PEDro and Cochrane training assessments were dis-
cussed in a group meeting to determine consistency in ratings, and calibrate assessments [21].
We defined trials of adequate quality as having adequate generation of random sequence, con-
cealment of allocation, and blinding of outcome assessors (based on the Cochrane RoB tool) or
as trials with a PEDro summary score of at least 5 or 6 points, the cutoffs widely used in the lit-
erature [12, 16–18].
Data extraction of treatment estimates and trial characteristics
Two reviewers independently extracted data on means, standard deviations, standard errors,
and sample sizes from each RCT. Data on the design of the trial, type of intervention (including
information on intensity, frequency, dosage), condition, outcome (objective, subjective), fund-
ing source, publication year, and statistical analysis were also collected. We defined outcomes
as objective or subjective following the approach by Wood et al [5].
Statistical analysis
We calculated the kappa (κ) statistics for categorical data to assess the agreement between the
PeDro scores and the Cochrane approach for classifying trial quality. We used the criteria pro-
posed by Byrt to interpret kappa values [22]: values of 0.93 to 1 represent excellent agreement;
0.81 to 0.92 very good agreement; 0.61 to 0.80 good agreement; 0.41 to 0.60 fair agreement;
0.21 to 0.40 slight agreement, 0.01 to 0.20 poor agreement; and less than 0.01 no agreement.
We calculated standardized effect sizes for each trial using Cohen’s approach [23] using
approximations when necessary [24]. We followed the Cochrane reviews to determine the
comparison included for analysis (i.e. treatment of interest and control group). The statistical
analysis allowed both for heterogeneity between trials within a meta-analysis and for heteroge-
neity between meta-analyses.[25] In a first step we used inverse-variance random-effects meta-
analyses to combine effect sizes across trials and calculated the DerSimonian and Laird
Treatment Effects Differed between PeDro Score and Cochrane Approach
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estimate of the between trial variance (tau squared).[26] Calculations were done separately for
trials classified as of adequate quality based on PEDro summary scores and for trials of ade-
quate quality according to the Cochrane RoB tool. We combined effect sizes from trials of ade-
quate quality according to PeDro scores or Cochrane approach for each meta-analysis.
Differences in combined estimates between PeDro and Cochrane were considered relevant
if they corresponded to 0.15 standard deviation units or more, a difference that corresponds to
a clinically relevant treatment effect [27–30].
Stata statistical software (version 12, College Station, Texas) was used to perform the analy-
ses. Results are presented as kappa statistics or standardized effect sizes with 95% confidence
intervals (CI). The study was approved by the Ethics Board of the University of Alberta
(Pro00038172).
Results
Selection and characteristics of meta-analyses and randomised trials
The search identified 3901 Cochrane reviews, with 271 reviews potentially relevant to physical
therapy. Of these, 68 reviews included a meta-analysis of at least three studies of physical ther-
apy interventions and used a continuous outcome. We randomly selected 42 meta-analyses but
excluded one [31] because it used follow-up data from the same group rather than a control
group for comparison (Fig 1). Forty-one meta-analyses, 353 trials and 42,342 patients contrib-
uted to the analysis. Table 1 and S2 Table detail the characteristics of the reviews. Briefly, the
reviews were published between 2008 and 2011 and included meta-analyses of the effectiveness
of physical therapy interventions for musculoskeletal (22 reviews) [32–40] cardiorespiratory (8
reviews) [41-48], neurological (6 reviews) [49–55], and other areas of physical therapy (5
reviews) [55–59]. A median number of 6 trials were included in each meta-analysis (interquar-
tile range 5–8). Most trials were parallel group trials (330; 93%), single-center studies (270;
76.5%) and had active control interventions (325; 91.5%). Trials compared two groups (222;
62.9%), three groups (82; 23.2%) or four or more groups (49; 13.9%). The most common inter-
vention was exercise (n = 246, 69.7%). Electrophysical agents, manual therapy, education, and
acupuncture were used in 15 (4.2%), 14 (4.0%), 10 (2.8%), and 8 trials (2.3%) respectively. The
remaining trials used a combination of exercise and physical agents, manual therapy and other
treatments such as respiratory exercises.
Trials of adequate quality according to PeDro scores and Cochrane RoB
tool
PEDro scores were obtained from the PEDro database for 333 trials (94.3%) and determined
by us for 20 trials (5.7%). Similarly, Cochrane RoB assessments were available from the
Cochrane reviews for 314 trials (89.0%) and done by us for 39 (11.0%) trials. A total of 97
(27.5%), 70 (19.8%), 50 (14.2%) and 36 (10.2%) trials had PEDro summary scores of 5, 6, 7, or
8 points, respectively. Among trials with PEDro summary scores of 5 (97 trials), only 11 trials
(11.3%) were of adequate quality according to the Cochrane RoB domain approach. The corre-
sponding numbers for 6, 7 or 8 points on the PEDro scale were 9 trials (12.9%), 14 trials (28%)
and 20 trials (55.6%) (Table 2). Only few trials of adequate quality based on the PeDro scale
had adequate allocation concealment or blinding of outcome assessors. For example, among
the 97 trials with a PEDro score of 5 points, only 21 (21.6%) had adequate concealment of allo-
cation and 23 trials (23.7%) had adequate blinding of assessors (Table 2).
Treatment Effects Differed between PeDro Score and Cochrane Approach
PLOS ONE | DOI:10.1371/journal.pone.0132634 July 10, 2015 4 / 14
Agreement on adequate quality between PeDro scores and Cochrane
RoB tool
Agreement between PeDro and Cochrane for the definition of adequate quality across all
meta-analyses was poor for PeDro scores>5 or more (kappa 0.12; 95% CI 0.07–0.16), slight
for a score>6 or more (kappa 0.24; 95% CI 0.16–0.32), and 7 or more (kappa 0.39; 95% CI
0.286–0.510), and fair (kappa 0.44; 95% CI 0.314–0.574) for 8 points and more (Fig 2).
Differences in treatment effects between trials of adequate quality trials
defined according to PEDro scores and Cochrane RoB tool
All 41 meta-analyses included adequate quality trials based on a PEDro score of 5 or more, and
37 (90.2%), 30 (73.2%) and 19 (46.3%) meta-analyses included adequate quality trials based on
scores of at least 6, 7 or 8. In contrast, 22 (53.7) meta-analyses did not include any adequate
quality trials using the Cochrane RoB domain approach (S3 Table). An extreme example was
the meta-analysis by Liu et al. [60] which included only one trial of adequate quality according
Fig 1. Diagram for identification of studies.
doi:10.1371/journal.pone.0132634.g001
Treatment Effects Differed between PeDro Score and Cochrane Approach
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to the Cochrane approach but 29, 18, 9, and 5 trials of adequate quality when using PeDro
scores of 5, 6, 7, and 8 points, respectively.
When combining effect sizes of trials deemed to be of adequate quality according to PEDro
or Cochrane criteria, we found that a substantial difference in the combined effect size (> 0.15)
was evident in 9 (22%) out of the 41 meta-analyses for PEDro cutoff>5 and 10 (24%) for the
cutoff>6 (Table 3). In addition to this difference, 19 and 15 systematic reviews (46% and 37%)
did not have adequate quality trials by Cochrane approach but they had trials of adequate qual-
ity by PeDro5 points and6 points respectively. Considering this as a discrepancy as well,
an overall discrepancy existed between 2 approaches in 28 meta-analyses (68%) and 25 meta-
analyses (61%) for PeDro5 points and6 points respectively.
Table 1. Meta-analysis and trial characteristics.
Meta-analyses Musculoskeletal Cardio-respiratory Neurology Other Total
Total No. of meta-analyses 22 8 6 5 41
Median No. of included trials (range) 6 (3–33) 7.5 (5–15) 6.5 (5–23) 6 (6–17) 6 (3–33)
Median No. of participants (range) 363 (122–3616) 1079 (201–3109) 282.5 (91–907) 556 (236–7598) 379 (91–7598)
Total No. of patients included 19861 8397 2138 11946 42,342
Main intervention
Exercise 13 6 3 4 30
Physical agents 1 0 1 0 2
Acupuncture 2 0 0 0 2
Manual therapy 1 0 0 0 1
Other 1 2 2 1 6
Outcomes
Clinician assessed outcome 8 4 6 3 21
Self-reported outcome 11 3 0 1 15
Administrative data/automated outcome/laboratory 3 1 0 1 5
Trials
Total No. of trials 192 67 52 42 353
Parallel group trial 190 62 47 40 339
Single center trial 150 49 43 32 274
Active control interventions 90 27 22 12 151
doi:10.1371/journal.pone.0132634.t001
Table 2. Distribution of 353 trials across PEDro scores and number of trials and percentage classified as of adequate quality according to the
Cochrane RoB tool.
PEDro
Score
Total No. of trials
(Column %)
No. of adequate quality
trials (row %)
No. of trials with adequate
concealment of allocation (row %)
No. of trials with adequate blinding of
outcome assessors (row %)
1 3 (0.8) 0 (0) 0 (0) 0 (0)
2 7 (2) 0 (0) 0 (0) 2 (28.6)
3 33 (9.3) 2 (5.7) 4 (12.1) 5 (15.1)
4 53 (15) 1 (1.9) 1 (1.9) 8 (15.4)
5 97 (27.5) 11 (11.3) 21 (21.6) 23 (23.7)
6 70 (19.8) 9 (12.9) 26 (37.1) 30 (42.9)
7 50 (14.2) 14 (28) 30(60) 23 (46)
8 36 (10.2) 20 (55.6) 29 (80.6) 24 (66.7)
9 4 (1.1) 3 (75.0) 4 (100) 43(75)
10 0 (0) 0 (0) 0 (0) 0 (0)
doi:10.1371/journal.pone.0132634.t002
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Discussion
In this meta-epidemiological study we found that depending on the approach used to assess
the risk of bias, PEDro scores or Cochrane criteria, different trials were considered to be of ade-
quate quality. Unsurprisingly the combined estimates of treatment effects from these adequate
quality trials differed substantially, depending on the approach chosen and the cutoff score
used to define adequate quality. This may have important implications for decision making
since different recommendations will be made based on different treatment effects obtained
from meta-analyses of trials considered of adequate quality.
There were substantial disagreements between the two methods regarding which and how
many trials are considered to be of adequate quality. Almost 60% of trials were considered to
be of adequate quality based on the PeDro cut off of5 points, which is widely used in the lit-
erature [12, 16–18]. However, many of these trials did not meet the accepted quality standards
such as generation of random sequence, concealment of allocation, and blinding of study asses-
sors defined by the Cochrane RoB tool. Previous studies have shown that these trial features
can have a substantial impact on the estimates of treatment effect [4, 5, 61–63]. For example,
inadequate allocation concealment may overestimate treatment effects by 5% to 30% [4, 5, 64–
66] and lack of double-blinding may overestimate effects by 9% to 44% [3, 5, 66]. Biased esti-
mates from individual trials can lead to biased results and misleading conclusions in systematic
reviews and meta-analyses [5, 61, 67–69]. This can in turn affect patient care through different
recommendations and decisions in clinical practice. Indeed, the differences observed in our
study are clinically relevant: in a substantial proportion of meta-analyses the differences in
effect sizes between the two approaches was 0.15 or greater. The typical treatment effect in
physical therapy is in the range of 0.1 to 0.8 [27–30].
Our results are consistent with studies [10–12] that showed that bias may be introduced
when summary quality scores are used as an eligibility criterion for trials to be included in sys-
tematic reviews and meta-analyses. Analyzing a smaller number of trials, Greenland [10], Colle
[70], and Juni and colleagues [11] showed that using different tools for evaluating quality of
primary research in meta-analyses can lead to different results. Summary scores dilute the
effect of items that are important for the risk of bias with items that are not related to the inter-
nal validity of trials, but to the quality of reporting of trials. Although transparent reporting is
important to assess the quality of trial conduct, a focus on quality of reporting in quality scores
can hide differences in trial conduct and lead to under- or over-estimation of the methodologi-
cal quality. [71]
Fig 2. Agreement between PeDro Score at different cut offs and Cochrane Approach.
doi:10.1371/journal.pone.0132634.g002
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Table 3. Combined effect sizes from trials of adequate quality using the PEDro or Cochrane approach to assess trials, and differences in effect
sizes between results obtained with Cochrane and PEDro.
Meta-analysis Pedro Cutoff 5 Pedro Cutoff 6 Cochrane Adequate Quality Difference Pedro-
Cochrane
No. of
trials
Combined effect
size (95%CI)
No. of
trials
Combined effect
size (95%CI)
No. of
trials
Combined effect
size (95%CI)
Pedro
Cutoff >5
Pedro
Cutoff >6
Pollock A, 2009 4 -0.28 (-0.59, 0.03) 4 -0.28 (-0.59, 0.03) 1 -0.34 (-0.66, -0.03) 0.06 0.06
States R, 2009 6 -0.44 (-0.89, 0.00) 5 -0.51 (-0.99, -0.03) 3 -0.34 (-0.71, 0.03) -0.1 -0.17*
Schaafsma F,
2011
5 -0.18 (-0.37, -0.00) 2 -0.23 (-0.57, 0.12) 3 -0.10 (-0.32, 0.11) -0.08 -0.13
Markes M, 2009 2 -0.46 (-1.02, 0.11) 0 NAQT 0 NAQT - -
McNeely M, 2010 3 -0.33 (-1.41, 0.75) 2 0.03 (-1.97, 2.03) 0 NAQT - -
Main E, 2010 1 8.26 (0.75, 15.77) 1 8.26 (0.75, 15.77) 0 NAQT - -
Davies E, 2010 8 -0.48 (-0.74, -0.23) 5 -0.35 (-0.63, -0.07) 1 -0.01 (-0.36, 0.35) -0.47* -0.34*
Busch A, 2008 5 -0.24 (-0.66, 0.18) 4 -0.28 (-0.85, 0.29) 1 -0.15 (-0.58, 0.28) -0.09 -0.13
Liu C, 2009 29 -0.14 (-0.24, -0.04) 18 -0.15 (-0.27, -0.04) 1 -0.09 (-0.72, 0.55) -0.05 -0.06
Furlan A, 2011 2 0.21 (-1.12, 1.54) 2 0.21 (-1.12, 1.54) 1 0.29 (-0.16, 0.74) -0.08 -0.08
Fransen M, 2009 5 -0.34 (-0.85, 0.17) 5 -0.34 (-0.85, 0.17) 4 -0.45 (-1.03, 0.14) 0.11 0.11
Ostelo R, 2011 2 -1.11 (-2.13, -0.09) 2 -1.11 (-2.13, -0.09) 0 NAQT - -
Taylor R, 2010 6 0.09 (-0.16, 0.34) 3 0.18 (-0.43, 0.79) 4 -0.12 (-0.39, 0.15) 0.21* 0.3*
Harvey L, 2010 6 -0.45 (-0.69, -0.21) 3 -0.44 (-0.72, -0.16) 3 -0.28 (-0.62, 0.07) -0.17* -0.16*
Mead GE, 2010 13 -0.87 (-1.27, -0.47) 7 -0.65 (-1.10, -0.20) 3 -0.41 (-0.83, 0.00) -0.46* -0.24*
Edmonds M, 2010 5 -0.78 (-1.28, -0.28) 3 -1.12 (-1.59, -0.66) 0 NAQT - -
Howe TE, 2008 3 -0.18 (-0.44, 0.09) 3 -0.18 (-0.44, 0.09) 1 -0.17 (-0.72, 0.38) -0.01 -0.01
Fransen M, 2009 28 -0.43 (-0.55, -0.32) 21 -0.36 (-0.45, -0.26) 10 -0.31 (-0.45, -0.16) -0.12 -0.05
Lin CH, 2008 3 -0.50 (-1.06, 0.06) 1 -0.14 (-0.49, 0.21) 3 -0.41 (-0.84, 0.02) -0.09 0.27*
Rutjes AW, 2010 5 -0.49 (-0.76, -0.23) 4 -0.43 (-0.74, -0.11) 0 NAQT - -
Woodford HJ,
2009
3 0.04 (-0.53, 0.61) 2 -0.02 (-0.66, 0.62) 0 NAQT - -
Saunders DH,
2009
5 -0.33 (-0.52, -0.13) 5 -0.33 (-0.52, -0.13) 0 NAQT - -
O'Brien K, 2010 3 -1.16 (-1.56, -0.76) 0 NAQT 0 NAQT - -
Sirtoti V, 2009 6 -0.37 (-0.68, -0.07) 5 -0.36 (-0.72, 0.00) 2 -0.40 (-1.12, 0.32) 0.03 0.04
Hayden J, 2011 13 -0.21 (-0.31, -0.11) 8 -0.19 (-0.30, -0.07) 0 NAQT - -
Orozco LJ, 2008 6 -0.22 (-0.42, -0.01) 5 -0.22 (-0.46, 0.02) 2 -0.46 (-0.54, -0.38) 0.24* 0.24*
De Morton N, 2009 2 -0.12 (-0.33, 0.09) 2 -0.12 (-0.33, 0.09) 0 NAQT - -
Mehrholz J, 2010 6 -0.53 (-0.89, -0.17) 0 NAQT 2 -0.25 (-0.90, 0.39) -0.28* -
Shaw K, 2009 9 -0.37 (-0.59, -0.14) 3 -0.24 (-0.51, 0.03) 0 NAQT - -
Handholl H, 2009 6 -0.10 (-0.37, 0.17) 5 -0.11 (-0.44, 0.22) 1 0.40 (0.16, 0.64) -0.5* -0.51*
Efﬁng T, 2009 6 -0.13 (-0.28, 0.01) 3 -0.10 (-0.29, 0.09) 2 -0.16 (-0.36, 0.05) 0.03 0.06
Bendermacher B,
2009
2 -1.17 (-1.65, -0.68) 0 NAQT 0 NAQT - -
Bonaiuti D, 2009 4 -0.63 (-1.12, -0.14) 2 -0.62 (-1.34, 0.11) 0 NAQT - -
Foster C, 2009 13 -0.18 (-0.32, -0.04) 5 -0.09 (-0.25, 0.07) 0 NAQT - -
Jolliffe J, 2009 7 -0.67 (-1.01, -0.32) 2 -0.70 (-1.76, 0.36) 1 -1.23 (-1.50, -0.95) 0.56* 0.53*
Katalinic O, 2010 6 0.22 (-0.13, 0.56) 6 0.22 (-0.13, 0.56) 5 0.27 (-0.16, 0.71) -0.05 -0.05
Puhan M, 2010 4 -0.70 (-1.28, -0.12) 2 -0.36 (-1.15, 0.42) 0 NAQT - -
Kramer M, 2010 1 -0.53 (-1.12, 0.06) 1 -0.53 (-1.12, 0.06) 0 NAQT - -
Rutjes AW, 2010 4 -1.55 (-2.21, -0.89) 2 -1.26 (-1.91, -0.61) 0 NAQT - -
Watson, 2008 5 -1.16 (-2.25, -0.06) 2 -1.05 (-3.63, 1.52) 0 NAQT - -
(Continued)
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Interestingly, despite having been developed for clinical trials of physical therapy the PEDro
scale does not contain items specific to this field. Because physical therapy clinical trials are
more complex than drug trials, compliance and standardization of treatment protocols, reliable
application of the intervention [72], and skills, training, and experience of therapists are all
issues of particular importance to physical therapy [73].
To the best of our knowledge, this is the first meta-epidemiological study addressing the
question of how best to assess trials for inclusion in meta-analyses in physical therapy. One of
the main strengths of this study is the large number of meta-analyses and trials included. Most
previous studies looked at one systematic review only [11, 12, 70]. We restricted our analysis to
Cochrane systematic reviews in physical therapy and results might not be applicable to all
Cochrane reviews conducted in other areas of research. However, similar results have been pre-
viously obtained in different areas of health research with smaller sample of trials and meta-
analyses [11, 12, 70]
In conclusion, we found that the PeDro and Cochrane approaches to identifying RCTs of
adequate quality lead to different sets of trials and different combined treatment estimates
from meta-analyses of these trials. A consistent approach to assessing RoB in trials of physical
therapy based on the Cochrane RoB tool rather than a summary score from the PEDro scale
should be adopted.
Supporting Information
S1 Appendix. Search strategy to identify systematic review in physical therapy from the
Cochrane Library of Systematic Reviews.
(DOC)
S1 Table. Items of the Physiotherapy Evidence Database (PEDro) scale.
(DOCX)
S2 Table. Characteristics of meta-analyses included in the study.
(DOCX)
S3 Table. Identity of trials of adequate quality based on different PeDro cutoffs, Cochrane
approach, and results from the original Cochrane review.
(DOC)
S4 Table. Data for manuscript.
(XLS)
Table 3. (Continued)
Meta-analysis Pedro Cutoff 5 Pedro Cutoff 6 Cochrane Adequate Quality Difference Pedro-
Cochrane
No. of
trials
Combined effect
size (95%CI)
No. of
trials
Combined effect
size (95%CI)
No. of
trials
Combined effect
size (95%CI)
Pedro
Cutoff >5
Pedro
Cutoff >6
Manheimer E,
2010
7 -0.29 (-0.48, -0.10) 7 -0.29 (-0.48, -0.10) 3 -0.14 (-0.34, 0.06) -0.15* -0.15*
NAQT; no adequate quality trial included in meta-analysis.
* Difference clinically relevant.
doi:10.1371/journal.pone.0132634.t003
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